




Infectious Diseases


High-quality products and high-standard quality control making Autobio the leadership in the market

Autobio Infectious Diseases




1st place of market share in China


- ① The Great Market Reputation;
- ② The Consistent Quality of The Product ;
- ③ Massive Market Application Data for Optimization of Product Performance;




Laboratory Ratio of HBsAg



Laboratory Ratio of Anti-HCV



Laboratory Ratio of HIV



Laboratory Ratio of Anti-TP

Dependable Quality - CE Certification

The CE certifications cover All core products.

- ✓ HBsAg-IVDR
- ✓ Anti-HCV-IVDR
- ✓ HIV Ag&Ab Combo-IVDR
- ✓ Anti-TP-IVDR
- ✓ HAV-IgM
- ✓ HEV-IgM
- ✓ HEV-IgG
- ✓ H.Pylori IgG



Dependable Quality - CE Certification

HBsAg	Autobio Results		HIV	Autobio Results		HCV	Autobio Results		TP	Autobio Results	
	Evaluation scheme	Final Report		Evaluation scheme	Final Report		Evaluation scheme	Final Report		Evaluation scheme	Final Report
Specificity	Blood donor	100.00% (5000/5000)	Specificity	Blood donor	99.84% (4998/5006)	Specificity			Specificity	Blood donor	99.9% (5009/5013)
	Inpatient	100.00% (200/200)		Inpatient	99.5% (200/201)		Blood donor	99.84% (5152/5160)		Inpatient	99.5%(208/209)
	Analysis specificity	100.00% (202/202)		Positive for Anti-E. Coli and HAMA	100% (10/10)		Inpatient	99.60% (251/252)		Total Specificity	99.83% (5403/5412)
	Total Specificity	100.00% (5402/5402)		Total Specificity	99.83% (5208/5217)		Total Specificity	99.83% (5403/5412)			
Sensitivity	Analysing sensitivity	< 0.130 IU/ml	Sensitivity	HIV-1 antibody positive	100% (348/348)	Sensitivity	Evaluation scheme	Final Report	Sensitivity	Evaluation scheme	Final Report
	Genotype ABCDEFGH	100% (160/160)		HIV-1 antibody positive, non-subtype B	100% (57/57)		Ordinary positive	100% (345/345)		weakly positive	64
	Positive(non-specific subtypes, genotypes)	100% (221/221)		Positive for HIV-1 reverse therapy population antigens or antibodies	100% (10/10)		Genotype	100% (92/92)		Congenital syphilis	6
	Subtypes	100% (20/20)		HIV-1 antigen and antibody positive	100% (50/50)		weakly positive	100% (51/51)		Neurosyphilis	6
	Seroconversion panel	30 groups with sensitivity greater than or equal to commercial HBsAg products					fresh-positive	100% (28/28)		Early syphilis	5
										second-phase syphilis	6
										Early latency	5
	Total Sensitivity	100% (401/401)		Total Sensitivity	100% (401/401)		Total Sensitivity	100% (516/516)		terminal syphilis	6
										Other positive	102
										Total Sensitivity	100%

*Data is from CE Evaluation reports.